TG Therapeutics Inc (NASDAQ: TGTX) is -18.56% lower on its value in year-to-date trading and has touched a low of $6.46 and a high of $35.67 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TGTX stock was last observed hovering at around $13.36 in the last trading session, with the day’s gains setting it 0.55%.
Currently trading at $13.91, the stock is -5.47% and -14.07% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.03 million and changing 4.12% at the moment leaves the stock -12.82% off its SMA200. TGTX registered -11.40% loss for a year compared to 6-month gain of 32.73%. The firm has a 50-day simple moving average (SMA 50) of $10.35 and a 200-day simple moving average (SMA200) of -$152.66.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -11.96% loss in the last 1 month and extending the period to 3 months gives it a 8.76%, and is 5.14% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.52% over the week and 5.01% over the month.
TG Therapeutics Inc (TGTX) has around 226 employees, a market worth around $2.11B and $189.77M in sales. Profit margin for the company is -13.65%. Distance from 52-week low is 115.33% and -61.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-9.48%).
TG Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.1 with sales reaching $40.06M over the same period.The EPS is expected to grow by 99.12% this year, but quarterly earnings will post 8,198.40% year-over-year. Quarterly sales are estimated to grow 49,975.00% in year-over-year returns.
TG Therapeutics Inc (TGTX) Top Institutional Holders
299 institutions hold shares in TG Therapeutics Inc (TGTX), with institutional investors hold 66.13% of the company’s shares. The shares outstanding are 146.39M, and float is at 136.40M with Short Float at 21.35%. Institutions hold 60.43% of the Float.
The top institutional shareholder in the company is Vanguard Group Inc with over 13.46 million shares valued at $334.22 million. The investor’s holdings represent 8.91% of the TGTX Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 9.92 million shares valued at $246.35 million to account for 6.57% of the shares outstanding. The other top investors are Darwin Global Management, Ltd. which holds 9.28 million shares representing 6.15% and valued at over $230.48 million, while FMR, LLC holds 4.03% of the shares totaling 6.08 million with a market value of $151.05 million.
TG Therapeutics Inc (TGTX) Insider Activity
A total of 5 insider transactions have happened at TG Therapeutics Inc (TGTX) in the last six months, with sales accounting for 1 and purchases happening 4 times. The most recent transaction is an insider sale by Charney Laurence N,the company’sDirector. SEC filings show that Charney Laurence N sold 17,500 shares of the company’s common stock on Jan 05 at a price of $19.03 per share for a total of $0.33 million. Following the sale, the insider now owns 0.24 million shares.
TG Therapeutics Inc disclosed in a document filed with the SEC on Jan 03 that Power Sean A (CFO) sold a total of 47,867 shares of the company’s common stock. The trade occurred on Jan 03 and was made at $16.91 per share for $0.81 million. Following the transaction, the insider now directly holds 0.61 million shares of the TGTX stock.
Still, SEC filings show that on Aug 11, WEISS MICHAEL S (CEO and President) acquired 100,000 shares at an average price of $10.13 for $1.01 million. The insider now directly holds 12,073,021 shares of TG Therapeutics Inc (TGTX).
TG Therapeutics Inc (TGTX): Who are the competitors?
The company’s main competitors (and peers) include Dr. Reddy’s Laboratories Ltd. ADR (RDY) that is trading 47.04% up over the past 12 months. Infinity Pharmaceuticals Inc. (INFIQ) that is -100.00% lower over the same period.
